However, the company managed to tick certain boxes that investors considered to be encouraging. Growth of its chronic business in India, ma...

Sandra Hagenbrock, who was national account director at Sun in the US and employed there from February 2016 to July 2019, alleged the compa...

Sun Pharma shares slip 4% after Sebi orders probe, close low at 415.90 on BSE.

Shares of Sun Pharma closed at Rs 431, up 1.30 per cent on the BSE on Thursday.

Sun complained that such access creates a "great asymmetry in the information circulating between analysts, investors and media, leading to...

Sun Pharma's stock tumbled to 6-month low after various allegations of misgovernance and insider trading.

The scrip was trading 9.08 per cent down at Rs 447.60 at around 09.37 am.

Alleged irregularities in raising funds through FCCBs are likely to be probed by the watchdog, said sources.

From a pure defensive stock, Sun Pharma has steadily become a high risk-high return proposition to invest in.

Earlier in September 2014, the Halol site came under the lens, receiving as many as 23 observations from the US agency.The inspection culmi...

The stock fell 2.69% to hit a low of Rs 668 on BSE.

An FDA audit of the Sun Pharma unit between November 17 and December 1 has revealed inadequately designed testing programmes to assess the ...

A total of seven companies have been issued warning letters this year by the US regulator, raising issues of manufacturing lapses at their ...

United States Food and Drug Administration had conducted inspections in January and May this year and had noticed the lapses.

After facing a regulatory clampdown by the US FDA in 2009, Caraco has had its manufacturing suspended. It now sells distributed products.

Sun Pharmaceuticals has been slapped with another lawsuit. The Mumbai-based pharma company has been sued by Taro Pharmaceuticals, the Israe...

After Ranbaxy, Sun Pharma's USbased subsidiary, Caraco has come under the glare of US Food and Drug Administration (FDA) for certain manufa...